298) to be significant predictors of past CBE use. |
299) between length of residence and substance use. |
300) th education background, approved of such use. |
301) isks related to their widespread clinical use. |
302) the role of family in SLT initiation and use. |
303) willingness of the poor to shift to their use. |
304) fficacy of a message for promoting condom use. |
305) CC values and recommendable for practical use. |
306) hildren was the perceived barrier to such use. |
307) , and which is subsequently removed after use. |
308) rder to help readers decide which tool to use. |
309) riginal tumors provide rational for their use. |
310) ffordability, accuracy and convenience in use. |
311) acy in vivo and consequently its clinical use. |
312) riminal career outcomes was juvenile drug use. |
313) mpetence and meaningfulness of their time use. |
314) effects of long-term withdrawal from drug use. |
315) mmobilized enzymes were hydrated prior to use. |
316) d perceptions about health effects of SLT use. |
317) but none have reached widespread clinical use. |
318) ent smoking and current smokeless tobacco use. |
319) man without a history of intravenous drug use. |
320) share program (PBSP) and promotion of its use. |
321) is there enough evidence to support their use? |
322) mediated the relationship between alcohol use and depressive symptoms. |
323) Despite widespread use and growing popularity, little is know |
324) viate regional differences in health care use and improve the overall health status |
325) The anticipated reduced costs, ease of use and increased mobility of patients usi |
326) Ongoing surveillance of supplement use and iodine status among pregnant and l |
327) ena™ system appears to be safe, easy to use and may represent a support technique |
328) oeconomic factors affecting contraceptive use and method choice among women of urban |
329) t important determinants of contraceptive use and method choice. |
330) e important determinants of contraceptive use and method preference. |
|